The Board of Directors of Alkem Laboratories at its meeting held today i.e.10 December 2024 approved the transfer of the trade generics business of the Company as a going concern, on a slump sale basis, to Alkem Wellness, a wholly owned subsidiary of the Company, incorporated in India. The transaction is proposed to be effected through a business transfer agreement and will be effective on or before 1 April 2025 or such other date as may be mutually agreed between the parties, subject to customary closing conditions.Powered by Capital Market - Live News

Net profit of Alkem Laboratories rose 10.98% to Rs 688.64 crore in the quarter ended September 2024 as against Rs 620.52 crore during the previous quarter ended September 2023. Sales declined 0.74% to Rs 3414.67 crore in the quarter ended September 2024 as against Rs 3440.17 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3414.673440.17 -1 OPM %22.0521.71 - PBDT859.17779.60 10 PBT780.26705.70 11 NP688.64620.52 11 Powered by Capital Market - Live News

Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live News

Alkem Laboratories has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc (Sonnet) to develop, manufacture and commercialise the drug candidate �SON-080� for the treatment of diabetic peripheral neuropathy in India. �SON-080� is Sonnet`s proprietary version of �atexakin alfa�. It has shown encouraging data in phase 1b clinical trial. The drug candidate was demonstrated to be well-tolerated and the pain and quality of life survey results suggested a potential for rapid improvement of peripheral neuropathy symptoms and post-dosing durability, compared to placebo controls. Under the licensing agreement, Alkem will carry out the clinical development of �SON-080� in India with support from Sonnet and enable global and India regulatory filings. Alkem has exclusive rights to develop, manufacture and commercialise the drug in India.Powered by Capital Market - Live News

Net profit of Alkem Laboratories rose 90.13% to Rs 545.16 crore in the quarter ended June 2024 as against Rs 286.73 crore during the previous quarter ended June 2023. Sales rose 2.16% to Rs 3031.82 crore in the quarter ended June 2024 as against Rs 2967.72 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales3031.822967.72 2 OPM %20.0813.11 - PBDT699.84425.26 65 PBT619.36352.85 76 NP545.16286.73 90 Powered by Capital Market - Live News